*Packaging may vary based on availability.
Generic for Protopic · Non-steroidal ointment · 30g
Tacrolimus 0.03% is the lower-concentration formulation of tacrolimus — same non-steroidal mechanism as 0.1%, same absence of atrophy risk, at a milder starting dose. FDA-approved for atopic dermatitis in patients aged 2 and older (0.1% is approved only for adults 16+).
In adult Fern patients, 0.03% is typically chosen when treating very sensitive or thin-skinned areas where even the absence of atrophy risk doesn’t justify the stronger concentration, or when a clinician wants a lower starting dose in a patient new to calcineurin inhibitors. It’s also used as maintenance after 0.1% has achieved initial clearance.
Identical mechanism to tacrolimus 0.1%: calcineurin inhibition → NFAT inactivation → reduced T-cell cytokine production (IL-2, IL-4, IL-5, IFN-γ). The difference is quantitative — lower concentration means less molecule delivered per application, and a milder but still meaningful anti-inflammatory effect.
For the face, eyelids, and neck, this level of inhibition is often sufficient because thinner stratum corneum in those areas provides better drug penetration. Transient burning and stinging on application is still present but typically milder than with 0.1%, since the TRPV1-mediated nociceptive effect also scales with concentration. Most patients see the reaction resolve within 3–5 days of consistent use.
Tacrolimus 0.03% has its own set of RCTs, separate from the 0.1% trials, confirming efficacy for mild-to-moderate atopic dermatitis. It consistently outperforms vehicle. Head-to-head trials against 0.1% show the higher concentration produces faster and more complete clearance in adults, but 0.03% still produces clinically meaningful responses, particularly for facial eczema where penetration compensates for lower concentration.
International guidelines list 0.03% as an appropriate option for sensitive-skin areas and mild-to-moderate adult AD. The long-term safety data — specifically the absence of histological atrophy — applies equally to both concentrations.
The main limitation of 0.03% in adults is potency adequacy. For moderate-to-severe eczema on the body, 0.03% is unlikely to be sufficient; for established, active, thick plaque disease on the trunk, mid-potency steroids or tacrolimus 0.1% are more appropriate. If you’re prescribed 0.03% and don’t see adequate improvement within 2 weeks, that’s the most likely explanation and your clinician can step up.
Do not use on actively infected skin. Disclose any history of recurrent herpes simplex (cold sores) to your clinician before starting. Tacrolimus carries an FDA boxed warning about a theoretical increased risk of lymphoma and skin cancer with long-term use; the signal came from animal studies at doses far above topical exposure and from organ-transplant patients on oral tacrolimus, and large post-marketing studies of topical use have not confirmed the risk. The same considerations apply as with 0.1%.
| Traditional | With Fern | |
|---|---|---|
| Doctor appointment | ~30 days to book | 5-hour clinician review |
| Getting the Rx | Separate pharmacy trip | Shipped to your door |
| Cost | Insurance + copays | $35/mo, no insurance |
| Follow-up | Second appointment | Message the care team |
Same molecule, lower concentration. In practice: 0.03% is typically used for milder presentations, sensitive areas, or as a starting dose; 0.1% is used for moderate-to-severe adult AD. If you’re not getting adequate control with 0.03%, escalating to 0.1% is the straightforward next step.
Generally yes — the stinging effect scales with concentration. If application-site burning was the main reason you stopped using tacrolimus in the past, 0.03% is worth trying. Many patients who couldn’t tolerate 0.1% tolerate 0.03% well enough to establish the desensitization period, after which the 0.1% can sometimes be re-introduced.
Yes, and this is a common clinical approach. Using a low-potency steroid to rapidly reduce acute inflammation, then transitioning to or adding tacrolimus 0.03% for maintenance, takes advantage of both mechanisms. Some clinicians also use them sequentially on different areas simultaneously — steroids on body sites, tacrolimus on facial or flexural sites.
Yes — this is one of the primary reasons tacrolimus is prescribed. If you want to reduce your dependence on topical steroids for facial or flexural eczema, tacrolimus 0.03% or 0.1% is specifically the tool for it. The goal is to use steroids for acute clearance and calcineurin inhibitors for maintenance, which reduces total steroid exposure meaningfully.
Report this at follow-up. The most common next steps are switching to tacrolimus 0.1% if the affected areas are appropriate for the higher concentration, adding a topical steroid for acute exacerbations, or evaluating whether the areas involved are appropriate for calcineurin inhibitor treatment at all. It doesn’t mean tacrolimus isn’t right for you — it may just be a concentration question.
Fern clinicians review every case individually. Most patients hear back in under 3 hours.
Start your assessment →This information is for educational purposes only and is not medical advice. Consult with a healthcare provider before starting any treatment.
“There’s a specific look I recognize in eczema patients who’ve been managing on their own too long. They’ve stopped believing it can get better. Fern shortens that window of suffering. It gets people into real treatment before hopelessness sets in.”